Next Article in Journal
Investigating the Impact of a Primary Tumor on Metastasis and Dormancy Using MRI: New Insights into the Mechanism of Concomitant Tumor Resistance
Previous Article in Journal
The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Tomography
Volume 2
Issue 1
10.18383/j.tom.2016.00115
tomography-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Tomography is published by MDPI from Volume 7 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Grapho, LLC.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis

by
Gary D. Luker
1,2,3,*,
Huong (Marie) Nguyen
4,
Benjamin A. Hoff
1,
Craig J. Galbán
1,
Diego Hernando
5,
Thomas L. Chenevert
1,
Moshe Talpaz
4,* and
Brian D. Ross
1,6
1
Center for Molecular Imaging, Department of Radiology, San Francisco, CA 94143-0628, USA
2
Departments of Biomedical Engineering, San Francisco, CA 94143-0628, USA
3
Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109-2200, USA
4
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI 48109-2200, USA
5
Department of Radiology, University of Wisconsin-Madison, Madison, WI, USA
6
Department of Biological Chemistry, University of Michigan, Ann Arbor, MI, USA
*
Authors to whom correspondence should be addressed.
Tomography 2016, 2(1), 67-78; https://doi.org/10.18383/j.tom.2016.00115
Submission received: 2 December 2015 / Revised: 2 January 2016 / Accepted: 3 February 2016 / Published: 1 March 2016
Versions Notes

Abstract

Myelofibrosis (MF) is a hematologic neoplasm arising as a primary disease or secondary to other blood malignancies. Both primary and secondary MF develop progressive fibrosis of bone marrow, displacing normal hematopoietic cells to other organs and disrupting normal production of mature blood cells. Activation of JAK2 signaling in hematopoietic stem cells commonly causes MF, and ruxolitinib, a drug targeting this pathway, is the preferred treatment for many patients. However, current measures of disease status in MF do not necessarily predict response to treatment with ruxolitinib or other drugs. Bone marrow biopsies are invasive and prone to sampling error, while measurements of spleen volume only indirectly reflect status of bone marrow. Toward the goal of developing an imaging biomarker for treatment response in MF, we present preliminary results from a prospective clinical study evaluating parametric response mapping (PRM) of quantitative Dixon MRI bone marrow fat fraction maps in four MF patients treated with ruxolitinib. PRM allows voxel-wise identification of temporal changes in quantitative imaging readouts, in this case bone marrow fat. We identified heterogeneous responses of bone marrow fat among patients and within different bone marrow sites in the same patient. Changes in bone marrow fat fraction also were discordant with reductions in spleen volume, the standard imaging metric for treatment response. This study provides initial support for PRM analysis of quantitative MRI of bone marrow fat to monitor therapy in MF, setting the stage for larger studies to further develop and validate this method as a complementary imaging biomarker.
Keywords: magnetic resonance imaging; bone marrow; myelofibrosis; ruxolitinib magnetic resonance imaging; bone marrow; myelofibrosis; ruxolitinib

Share and Cite

MDPI and ACS Style

Luker, G.D.; Nguyen, H.; Hoff, B.A.; Galbán, C.J.; Hernando, D.; Chenevert, T.L.; Talpaz, M.; Ross, B.D. A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis. Tomography 2016, 2, 67-78. https://doi.org/10.18383/j.tom.2016.00115

AMA Style

Luker GD, Nguyen H, Hoff BA, Galbán CJ, Hernando D, Chenevert TL, Talpaz M, Ross BD. A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis. Tomography. 2016; 2(1):67-78. https://doi.org/10.18383/j.tom.2016.00115

Chicago/Turabian Style

Luker, Gary D., Huong (Marie) Nguyen, Benjamin A. Hoff, Craig J. Galbán, Diego Hernando, Thomas L. Chenevert, Moshe Talpaz, and Brian D. Ross. 2016. "A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis" Tomography 2, no. 1: 67-78. https://doi.org/10.18383/j.tom.2016.00115

APA Style

Luker, G. D., Nguyen, H., Hoff, B. A., Galbán, C. J., Hernando, D., Chenevert, T. L., Talpaz, M., & Ross, B. D. (2016). A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis. Tomography, 2(1), 67-78. https://doi.org/10.18383/j.tom.2016.00115

Article Metrics

Back to TopTop